Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Atossa Therapeutics Inc ATOS

Healthcare Biotechnology
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen... see more

Recent & Breaking News (NDAQ:ATOS)

Potential Life Saving COVID-19 Survival Manual Removed from Amazon Kindle Store Three Days before Official Launch

PR Newswire June 5, 2020

SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January 2020

GlobeNewswire May 29, 2020

Atossa Therapeutics Announces Second COVID-19 Therapeutic Development Program, AT-301 Nasal Spray: Summit Biosciences Retained to Develop and Supply AT-301 Nasal Spray for Clinical Study

GlobeNewswire May 28, 2020

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

GlobeNewswire May 20, 2020

Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs

GlobeNewswire May 13, 2020

Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment

GlobeNewswire May 7, 2020

Atossa Therapeutics Receives FDA Feedback on Two Ongoing Programs

GlobeNewswire May 7, 2020

Atossa Therapeutics Contracts with NYC Health + Hospitals/Metropolitan for COVID-19 HOPE Clinical Study

GlobeNewswire April 27, 2020

Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study

GlobeNewswire April 20, 2020

COVID-19 "Cease Fire" for the United States on April 23, 2020 and successful 'Opening Up America Again' initiative predicted

GlobeNewswire April 17, 2020

Atossa Therapeutics Launches COVID-19 HOPE Drug Development Program

GlobeNewswire April 16, 2020

Atossa Therapeutics Announces Clinical Progress

GlobeNewswire April 2, 2020

New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients

GlobeNewswire March 30, 2020

Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update

GlobeNewswire March 26, 2020

Atossa Therapeutics Announces Upcoming Meeting with FDA

GlobeNewswire March 13, 2020

Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

GlobeNewswire March 2, 2020

Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference

GlobeNewswire February 5, 2020

Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment"

Accesswire February 4, 2020

Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020

GlobeNewswire January 22, 2020

Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.

GlobeNewswire January 6, 2020